The jab averse can now rejoice! Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Forget injections. A new drug promises to be just as effective as Ozempic — but is taken as a daily pill. Called orforglipron, the results of a new clinical trial announced Thursday by ...

Illustration: Elizabeth Smelov The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes ...

When taken for 40 weeks for type 2 diabetes, orforglipron resulted in an average loss of 16 pounds, or about 7.9% of the patient's body weight, at the highest dose. HealthDay News — A new pill ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill. The ACHIEVE-1 trial ...

It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions. The pill form could expand access and reduce costs compared with injectable GLP-1 drugs. The move ...

On April 14, Pfizer announced it would discontinue development of an experimental weight-management pill. Pfizer is facing ... market exclusivity for Eliquis. Sales of the oral blood thinner ...

"The red pill is like, 'I see the truth.' It’s a call to action by the manosphere,” Adam, played by Amari Bacchus, says in the show about an Instagram comment. “She’s saying he’s an ...

Pfizer ends development of potential pill obesity treatment Pfizer signage is displayed at the Pfizer NYC Headquarters, Thursday, April 10, 2025, in New York. (AP Photo/Yuki Iwamura) · Associated ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...